Regulatory Requirements on Parenteral Dosage Forms – A Comparative Analysis of CDSCO (INDIA) and DDF (CAMBODIA)

Parenteral products enter directly into the bloodstream or other sterile body cavities; any failure in sterility or pyrogen control can therefore be fatal. India’s Central Drugs Standard Control Organization (CDSCO) and Cambodia’s Department of Drugs and Food (DDF) impose distinct—but increasingly convergent—regulatory frameworks to safeguard these medicines. Using document analysis of primary statutes, 2023-2025 draft amendments and technical guidance, this study compares nine domains: dossier structure, good manufacturing practice (GMP), quality control, labelling, pharmacovigilance, clinical data, timelines, user fees and intellectual-property protection. CDSCO’s reviewed Schedule M introduces ISO-class cleanrooms, media-fill twice yearly and real-time environmental monitoring, whereas DDF relies on ASEAN Common Technical Dossier (ACTD) and WHO-GMP while fast-tracking import licenses to bolster access. India mandates local bioequivalence (BE) for most generic injectables and endotoxin limits , while Cambodia grants BE waivers for well-established therapeutic classes to attract investment. Timelines average nine months in India and twelve in Cambodia, but Cambodian fees remain lower. Alignment opportunities include mutual GMP recognition and a shared e-submission portal. Findings assist manufacturers in dossier planning and support regulators in harmonizing approvals without flexible patient safety.